913 results on '"Visakorpi, Tapio"'
Search Results
252. DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer
253. Abstract 3576: USP22 modulates AR activity to critically regulate prostate cancer progression.
254. Abstract 667: Prognostic value and functional impact of aberrant GABRE∼miR-452∼miR-224 promoter methylation in prostate cancer.
255. Abstract 5217: Integrative sequencing reveals novel alterations in untreated and castration resistant prostate cancer.
256. 205 TMPRSS2-ERG GENE FUSION: FREQUENCY AND PROGNOSTIC SIGNIFICANCE IN PROSTATE CANCER PATIENTS WITH POSITIVE LYMPH NODES
257. HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk
258. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
259. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
260. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients
261. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus
262. The Role of Genetic Markers in the Management of Prostate Cancer
263. Novel endocrine aspects of prostate cancer
264. Androgen receptor (AR) aberrations in castration-resistant prostate cancer
265. Detection of smell print differences between nonmalignant and malignant prostate cells with an electronic nose
266. Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate
267. Chemical castration and anti‐androgens induce differential gene expression in prostate cancer
268. Abstract 5198: Elucidation of dynamic prostate epithelial hierarchy: Insights into transcriptional and epigenetic regulatory mechanisms
269. Faculty Opinions recommendation of Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.
270. 470 EXPRESSION OF ERG ONCOPROTEIN IS LESS FREQUENTLY AND ASSOCIATED WITH A LESS AGGRESSIVE TUMOR PHENOTYPE IN JAPANESE PROSTATE CANCER PATIENTS
271. Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth
272. Abstract A9: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
273. Abstract A28: Correlation of ERG expression with other genetic and expression abnormalities in prostate cancer
274. Abstract A50: Cyclin D1 isoforms selectively manipulate AR signaling to promote metastatic phenotypes in early and castration-resistant prostate cancer.
275. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
276. Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure
277. Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells
278. Overall and worst gleason scores are equally good predictors of prostate cancer progression
279. Faculty Opinions recommendation of Abiraterone and increased survival in metastatic prostate cancer.
280. Immunohistochemical ETS‐related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients
281. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer
282. MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
283. Abstract 4906: A systems approach into studying the changes in genetic regulation during prostate cancer progression
284. Abstract 4194: Constitutive DNA-damage signaling promotes cancer cell proliferation through Chk1-CIP2A pathway independent of ATM-ATR
285. Abstract 3060: Target genes of chromosomal 9p13.3 amplification in prostate cancer
286. The miR‐15a‐miR‐16‐1 locus is homozygously deleted in a subset of prostate cancers
287. ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells
288. Faculty Opinions recommendation of Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
289. Faculty Opinions recommendation of 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood.
290. Androgen regulation of micro‐RNAs in prostate cancer
291. Allelic Variation at the 8q23.3 Colorectal Cancer Risk Locus Functions as a Cis-Acting Regulator of EIF3H
292. Probabilistic analysis of gene expression measurements from heterogeneous tissues
293. Faculty Opinions recommendation of Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
294. Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer
295. Abstract 4449: Effects of endocrine therapy on mRNA- and microRNA expression profiles in prostate cancer
296. Abstract 4093: miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer
297. Abstract 2942: The effect of AR expression level on the chromatin binding of the receptor
298. Genetic alterations and changes in expression of histone demethylases in prostate cancer
299. Faculty Opinions recommendation of Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
300. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.